Ipsen (FR:IPN) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ipsen has expanded its agreement with Exelixis, leveraging promising results from the CABINET Phase III trial to potentially market Cabometyx® for advanced neuroendocrine tumors in territories excluding the U.S. and Japan. The trial showed a significant improvement in progression-free survival for patients with advanced pancreatic and extra-pancreatic neuroendocrine tumors. Ipsen is now in discussions with EU regulatory authorities to pursue marketing authorizations based on these clinical findings.
For further insights into FR:IPN stock, check out TipRanks’ Stock Analysis page.